Local adverse reaction rates decreased over time during treatment with recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin G (fSCIG) in patients with primary immunodeficiency diseases in the fSCIG phase 3 studies

Local adverse reaction rates decreased over time during treatment with recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin G (fSCIG) in patients with primary immunodeficiency diseases in the fSCIG phase 3 studies

Background: fSCIG can be administered at similar doses/volumes and dosing intervals as intravenous immunoglobulin G (IgG) (IVIG) but, similar to conventional subcutaneous IgG, is associated with a lower risk of systemic and higher risk of local adverse reactions (ARs). Objective: We report local AR...

Full description

Bibliographic Details
Main Authors: Lina Laguado, Mark Stein, Richard L. Wasserman, Isaac Melamed, Sudhir Gupta, Lisa Kobrynski, Arye Rubinstein, Christopher J. Rabbat, Werner Engl, Barbara McCoy, Heinz Leibl, Leman Yel
Format: Article
Language:English
Published: Colegio Mexicano de Inmunología Clínica y Alergia, A.C. 2018-06-01
Series:Revista Alergia México
Subjects:
recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin g
primary immunodeficiency diseases
Online Access:http://revistaalergia.mx/ojs/index.php/ram/article/view/495

Internet

http://revistaalergia.mx/ojs/index.php/ram/article/view/495

Similar Items